| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
| Targets |
The primary molecular targets of Uridine triphosphate trisodium salt are the P2Y receptors, a family of G-protein-coupled receptors that are activated by extracellular nucleotides. UTP acts as an agonist at P2Y receptors, including P2Y2 and P2Y4, which are involved in various physiological processes, including vasodilation, platelet aggregation, and immune responses. UTP is also a precursor in RNA biosynthesis, where it serves as a substrate for RNA polymerase. It is used as a substrate for the reduction reaction to form dUTP, which is used in DNA synthesis.
|
|---|---|
| ln Vitro |
In vitro, Uridine triphosphate trisodium salt is used as a substrate for RNA polymerase in the enzymatic biosynthesis of RNA. It is also used as a substrate for the reduction reaction to form dUTP. As a P2Y receptor agonist, UTP is used in studies of purinergic signaling. It induces contractile responses in some tissues and acts as a potent vasodilator. The compound is used in various biochemical and cell-based assays to study nucleotide signaling and metabolism. Its purity and stability are assessed by HPLC and other analytical methods.
|
| ln Vivo |
In vivo, Uridine triphosphate trisodium salt is used in studies of purinergic signaling and vasodilation. As a P2Y receptor agonist, it induces vasodilation and modulates various physiological processes. It is used in animal models to study the role of P2Y receptors in cardiovascular function, inflammation, and other processes. In vivo protocols typically involve administration of UTP via intravenous or intraperitoneal injection. Endpoints include assessment of blood pressure, vascular function, and inflammatory markers. However, detailed in vivo protocols are not extensively reported.
|
| Enzyme Assay |
For P2Y receptor assays, cells expressing P2Y receptors are cultured and loaded with a calcium-sensitive dye (e.g., Fluo-4 AM). Uridine triphosphate trisodium salt is dissolved in water or buffer and added to the cells at varying concentrations (0.001-100 µM). Calcium mobilization is measured using a fluorescence plate reader. EC50 values are calculated from dose-response curves. For in vitro transcription assays, UTP is used as a substrate for RNA polymerase in a reaction containing template DNA, RNA polymerase, and other NTPs. RNA synthesis is measured by incorporation of radiolabeled or fluorescently labeled nucleotides.
|
| Cell Assay |
For cellular studies, cells expressing P2Y receptors are cultured in appropriate medium with 10% FBS and antibiotics. Cells are seeded in 96-well plates. Uridine triphosphate trisodium salt is dissolved in water or buffer and diluted in culture medium to final concentrations (typically 0.001-100 µM). Cells are treated with UTP for 5-30 minutes. Calcium mobilization is measured using a fluorescence plate reader. For RNA synthesis studies, cells are labeled with [³H]-uridine or other labeled precursors, and RNA synthesis is measured.
|
| Animal Protocol |
For in vivo studies, animal models of cardiovascular disease or inflammation are used. Uridine triphosphate trisodium salt is formulated in vehicle and administered intravenously or intraperitoneally at doses determined from preliminary studies. Blood pressure and heart rate are monitored. Vascular function is assessed by measuring vessel diameter or blood flow. Inflammatory markers are measured in blood and tissues. For pharmacokinetic studies, blood samples are collected at various time points for compound quantification by LC-MS.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Uridine triphosphate trisodium salt indicate that it is rapidly metabolized in the body. As a nucleotide, UTP is hydrolyzed by ectonucleotidases to uridine diphosphate (UDP) and uridine monophosphate (UMP). The compound has a short half-life in circulation. It is used as a substrate in enzymatic reactions and is not intended for therapeutic use.
|
| Toxicity/Toxicokinetics |
Toxicological data for Uridine triphosphate trisodium salt are limited, as the compound is used as a research reagent. No acute toxicity, organ-specific toxicity, or mutagenicity data have been reported. As with all chemical reagents, appropriate safety precautions should be taken when handling Uridine triphosphate trisodium salt, including the use of personal protective equipment and work in a well-ventilated area.
|
| References |
|
| Additional Infomation |
Uridine triphosphate trisodium salt (CAS 19817-92-6), also known as UTP, is a polyphosphate analogue of uridine used in the synthesis of P2Y receptor agonists. It has a molecular formula of C₉H₁₂N₂Na₃O₁₅P₃ and a molecular weight of 550.09 (anhydrous basis). UTP is used as a precursor in RNA biosynthesis, a potent vasodilator, and induces contractile responses. It is a substrate for dUTP formation and in vitro RNA transcription. The compound is a P2Y receptor agonist. It is strictly for research use only.
|
| Molecular Formula |
C9H12N2NA3O15P3
|
|---|---|
| Molecular Weight |
550.0866
|
| Exact Mass |
549.914
|
| CAS # |
19817-92-6
|
| PubChem CID |
88265
|
| Appearance |
White to off-white solid powder
|
| Density |
2.106g/cm3
|
| Boiling Point |
>110°C
|
| Melting Point |
140 °C
|
| Flash Point |
113 °C
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
32
|
| Complexity |
820
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+]
|
| InChi Key |
MMJGIWFJVDOPJF-LLWADOMFSA-K
|
| InChi Code |
InChI=1S/C9H15N2O15P3.3Na/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18;;;/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18);;;/q;3*+1/p-3/t4-,6-,7-,8-;;;/m1.../s1
|
| Chemical Name |
trisodium;[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~75 mg/mL (~136.34 mM)
DMSO : ~10 mg/mL (~18.18 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (1.82 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1 mg/mL (1.82 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 1 mg/mL (1.82 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Solubility in Formulation 4: 100 mg/mL (181.79 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8179 mL | 9.0894 mL | 18.1788 mL | |
| 5 mM | 0.3636 mL | 1.8179 mL | 3.6358 mL | |
| 10 mM | 0.1818 mL | 0.9089 mL | 1.8179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
